کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5888444 | 1568019 | 2015 | 6 صفحه PDF | دانلود رایگان |
- PDL-0101 contains EPA+astaxanthin and γ/δ-tocotrienols, including geranylgeraniol.
- This was a randomized, double-blind, controlled trial in adults with elevated TAG.
- Eight-week treatment with PDL-0101 significantly reduced TAG vs. placebo.
- LDL-C, HDL-C, and oxidized LDL were not significantly altered with PDL-0101.
- PDL-0101 is an effective medical food for the management of elevated TAG.
This randomized, double-blind, placebo-controlled multi-center trial investigated the lipid-altering effects of a medical food (PDL-0101) providing 1.8 g/d eicosapentaenoic acid; 12 mg/d astaxanthin, a marine algae-derived carotenoid; and 100 mg/d tocopherol-free gamma/delta tocotrienols enriched with geranylgeraniol, extracted from annatto, on triacylglycerols (TAG), other lipoprotein lipids, and oxidized low-density lipoprotein (LDL) in 102 subjects with TAG 150-499 mg/dL (1.69-5.63 mmol/L) and LDL cholesterol (LDL-C) â¥70 mg/dL (1.81 mmol/L). Compared to placebo, after eight weeks of treatment, PDL-0101 significantly reduced median TAG (â9.5% vs. 10.6%, p<0.001), while not significantly altering mean LDL-C (â3.0% vs. â8.0% for PDL-0101 and placebo, respectively, p=0.071), mean high-density lipoprotein cholesterol (~3% decrease in both groups, p=0.732), or median oxidized LDL concentrations (5% vs. â5% for PDL-0101 and placebo, respectively, p=0.112). These results demonstrate that PDL-0101 is an effective medical food for the management of elevated TAG.
Journal: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) - Volume 99, August 2015, Pages 41-46